The Alzheimer's Association is a US-based voluntary health organization founded in 1980. It leads efforts to end Alzheimer's disease and other dementias through accelerated global research, risk reduction, early detection, and improved care and support. The organization funds over $490 million in research projects across 59 countries, provides millions of care consultations and support services annually, and hosts the annual Alzheimer's Association International Conference (AAIC).
16 abstracts cover Kisunla long‑term extension safety/biomarker data and P‑tau217 blood test performance versus amyloid PET at AAIC 2026.
